- Abstract
- Core Tip
- Article Highlights
- Full Article (PDF)
- Full Article (WORD)
- Full Article (HTML)
- Audio
- PubMed Central
- PubMed
- CrossRef
- Google Scholar
- Similar Articles (33)
- Timeline of Article Publication Processes (9)
- Article Quality Tracking (1)
- Reference Citation Analysis (System.Threading.Tasks.Task`1[System.Int32])
-
Full Article (HTML) (164) -
Full Article (PDF) (59) -
Send to Friends (0)
Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Checklist of Responsibilities for the Scientific Editor of This Article
Publishing Process of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (4331)
All Articles published online
|
Publishing Process of This Article
|
Dec 14, 2019 (publication date) through Jun 26, 2022
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Kim SJ, Chung JW, Woo HS, Kim SY, Kim JH, Kim YJ, Kim KO, Kwon KA, Park DK. Two-week bismuth-containing quadruple therapy and concomitant therapy are effective first-line treatments for Helicobacter pylori eradication: A prospective open-label randomized trial. World J Gastroenterol 2019; 25(46): 6790-6798 [PMID: 31857780 DOI: 10.3748/wjg.v25.i46.6790] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v25/i46/6790.htm |
| Number | Citing Articles |
| 1 |
Yeon‐Ji Kim, Woo Chul Chung, Dae Bum Kim.
Efficacy of bismuth added to standard triple therapy as the first‐line eradication regimen for
Helicobacter pylori
infection
. Helicobacter 2021; 26(3) doi: 10.1111/hel.12792
|
| 2 |
David Mathew Thomas, Krishnadas Devadas.
Bismuth‐based quadruple therapy vs concomitant therapy for
Helicobacter pylori
eradication—a real‐world experience
. GastroHep 2021; 3(6): 388 doi: 10.1002/ygh2.486
|
| 3 |
Su Young Kim, Jun-Won Chung. Best Helicobacter pylori Eradication Strategy in the Era of Antibiotic Resistance. Antibiotics 2020; 9(8): 436 doi: 10.3390/antibiotics9080436
|
| 4 |
Sung Eun Kim, Hye-Kyung Jung, Seung Joo Kang, Yong Chan Lee, Hyo-Joon Yang, Seon-Young Park, Cheol Min Shin, Hyun Chul Lim, Jie-Hyun Kim, Su Youn Nam, Woon Geon Shin, Jae Myung Park, Il Ju Choi, Jae Gyu Kim, Miyoung Choi. A 10- or 14-day Bismuth-containing Quadruple Therapy as a First-line Helicobacter pylori Eradication Therapy: A Systematic Review and Meta-analysis. The Korean Journal of Helicobacter and Upper Gastrointestinal Research 2021; 21(1): 48 doi: 10.7704/kjhugr.2020.0052
|
| 5 |
Anthony O'Connor, Takahisa Furuta, Javier P. Gisbert, Colm O'Morain.
Review – Treatment of
Helicobacter pylori
infection 2020
. Helicobacter 2020; 25(S1) doi: 10.1111/hel.12743
|
| 6 |
Diego Reyes, Javier Ortiz, Eduardo Fuentes-López, Sigall Budnik, Vicente Gándara, Andrea Gallardo, María Francisca Seydewitz, Roberto Candia, José Ignacio Vargas, María Paz Rollan, Javiera Godoy, Antonio Rollan, Rodrigo Mansilla, Alex Arenas, Javier Chahuán, Alberto Espino, Margarita Pizarro, Arnoldo Riquelme. Terapias cuádruples son superiores a terapia triple estándar en primera línea de erradicación de Helicobacter pylori en Chile. Gastroenterología y Hepatología 2021; doi: 10.1016/j.gastrohep.2021.11.010
|
| 7 |
Gyu Young Pih, Kee Don Choi, Eun Jeong Gong, Hee Kyong Na, Ji Yong Ahn, Jeong Hoon Lee, Kee Wook Jung, Do Hoon Kim, Ho June Song, Gin Hyug Lee, Hwoon‐Yong Jung.
Modified bismuth quadruple therapy with low‐dose metronidazole as first‐line therapy for
Helicobacter pylori
infection
. Helicobacter 2021; 26(1) doi: 10.1111/hel.12759
|
| 8 |
Caiqi Liu, Yuan Wang, Jiaqi Shi, Chunhui Zhang, Jianhua Nie, Shun Li, Tongsen Zheng. The status and progress of first-line treatment against Helicobacter pylori infection: a review. Therapeutic Advances in Gastroenterology 2021; 14: 175628482198917 doi: 10.1177/1756284821989177
|
| 9 |
Young-Il Kim, Jong Yeul Lee, Chan Gyoo Kim, Boram Park, Jin Young Park, Il Ju Choi. Ten-day bismuth-containing quadruple therapy versus 7-day proton pump inhibitor-clarithromycin containing triple therapy as first-line empirical therapy for the Helicobacter pylori infection in Korea: a randomized open-label trial. BMC Gastroenterology 2021; 21(1) doi: 10.1186/s12876-021-01680-1
|
| 10 |
Youn I Choi, Jun-Won Chung, Kyoung Oh Kim, Kwang An Kwon, Yoon Jae Kim, Jung Ho Kim, Ja Young Seo, Dong Kyun Park. Tailored eradication strategy <i>vs</i> concomitant therapy for <i>Helicobacter pylori</i> eradication treatment in Korean patients. World Journal of Gastroenterology 2021; 27(31): 5247-5258 doi: 10.3748/wjg.v27.i31.5247
|
| 11 |
Sotirios Georgopoulos, Vasilios Papastergiou. An update on current and advancing pharmacotherapy options for the treatment of H. pylori infection. Expert Opinion on Pharmacotherapy 2021; 22(6): 729 doi: 10.1080/14656566.2020.1845649
|
| 12 |
Erick A. Argueta, Steven F. Moss. Management of Helicobacter pylori. Current Opinion in Gastroenterology 2020; 36(6): 518 doi: 10.1097/MOG.0000000000000678
|